Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;8(3):181-9.
doi: 10.14740/jocmr2419w. Epub 2016 Jan 26.

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

Shabnam Momtahen  1 , John Curtin  2 , Khush Mittal  3
Affiliations
Review

Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma

Shabnam Momtahen et al. J Clin Med Res. 2016 Mar.

Abstract

A variety of chemotherapeutic agents have been used for treating recurrent or advanced stage uterine leiomyosarcoma (ULMS). The response rates of these current agents are disappointing, with partial response rates varying from 0% to 33%, and complete response rates varying from 0% to 8%. Recent studies have documented many molecular changes in ULMSs. Prominent amongst these are gains of growth factors C-MYC, Bcl-2, K-ras, and Ki-67, and losses in tumor suppressors p16, p53, Rb1, ING2 and D14S267. Various techniques that have been used to target these molecules are presented. Targeting specific therapies at these underlying molecular changes could potentially yield better response rates with fewer side effects.

Keywords: Chemotherapy; Leiomyosarcoma; Oncogenes; Uterus.

PubMed Disclaimer

References

    1. Wang WL, Soslow R, Hensley M, Asad H, Zannoni GF, de Nictolis M, Branton P. et al. Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases. Am J Surg Pathol. 2011;35(4):522–529. doi: 10.1097/PAS.0b013e31820ca624. - DOI - PubMed
    1. Gadducci A, Landoni F, Sartori E, Zola P, Maggino T, Lissoni A, Bazzurini L. et al. Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol. 1996;62(1):25–32. doi: 10.1006/gyno.1996.0185. - DOI - PubMed
    1. Echt G, Jepson J, Steel J, Langholz B, Luxton G, Hernandez W, Astrahan M. et al. Treatment of uterine sarcomas. Cancer. 1990;66(1):35–39. doi: 10.1002/1097-0142(19900701)66:1<35::AID-CNCR2820660108>3.0.CO;2-V. - DOI - PubMed
    1. Naaman Y, Shveiky D, Ben-Shachar I, Shushan A, Mejia-Gomez J, Benshushan A. Uterine sarcoma: prognostic factors and treatment evaluation. Isr Med Assoc J. 2011;13(2):76–79. - PubMed
    1. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112(4):820–830. doi: 10.1002/cncr.23245. - DOI - PubMed

LinkOut - more resources